Sangui BioTech GmbH press releases:
Sangui BioTech:
- Sales of USD 164,366 in first three quarters
- Decline in sales and earnings
Hamburg, May 11, 2026:
In the first nine months of fiscal year 2026 (to 30/06/2026) Sangui BioTech International Inc. achieved revenues from royalty income of USD 164,366. In the same period of the previous year the comparable revenue amounted to USD 256,006. Due to lower revenues of the wound spray Granulox, the resulting royalty income in the first nine-month period of the year decreased by 36% compared to the same period of the previous year.
Operating expenses decreased USD 8,679 or 8% to USD 106,805 during the first three quarters. As a result of the above factors, the nine-month operating result decreased USD 82,961 from USD 140,522 to USD 57,561.
Whereas in the same period of the previous year there was a loss in the valuation of loans denominated in EURO due to the development of the US dollar against the euro, there was a gain in the reporting period. Taking into account lower interest expenses in the reporting period, the result for the first three quarters of fiscal 2026 was a profit of USD 47,983 compared to profit of USD 101,949 in the same period last year.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the pink marketplace operated by OTC Markets Group Inc. Companies are current in their reporting and undergo an annual verification and management certification process. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
PDF Download